Plain-English translation of NCT06810505 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a medication already approved for migraine prevention in adults, works safely and effectively to prevent chronic migraines in teenagers aged 12 to 17. Half of the participants will take the medication once daily, and half will take a placebo (a pill with no medicine in it) for 12 weeks. Neither you nor your doctor will know which one you're getting, so researchers can fairly compare how well the treatment works.
has shown promise in preventing migraines in adults, but we don't yet know if it's safe and effective for teenagers. This study aims to fill that gap so that if this medication does work, doctors will have another tool to help young people who suffer from chronic migraines.
You likely qualify if…
You likely don't qualify if…
You will visit a clinic or hospital regularly over 16 weeks (12 weeks taking the study medication or placebo, plus 4 weeks of follow-up). You'll take one tablet by mouth every day, keep a daily diary on your phone or computer about your headaches, have blood tests done, and answer questions about how you're feeling. Your doctor will check for any side effects and watch how well the treatment is working.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States